The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...
Janina Krumbeck, PhD, discusses the clinical advantages of next-generation sequencing over traditional culture and how this untargeted diagnostic approach provides comprehensive pathogen ...
This image illustrates the typical steps in next-generation sequencing (excluding single-molecule sequencing methods). The process begins with isolating genomic DNA (a) and breaking it into short ...
The Next Generation Sequencing (NGS) field has been in constant flux since a wave of newcomers entered the field several years ago that changed the game. The startups offered sequencing users new ...
For decades, formalin-fixing paraffin-embedding has been the preferred method for preserving biological samples for diagnostic research. Formalin is relatively inexpensive and can be used to preserve ...
Complicated molecular alterations in tumors generate various mutant peptides. Some of these mutant peptides can be presented to the cell surface and then elicit immune responses, and such mutant ...
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...
NGS continually delivers breakthroughs in genomics, and to do so, it relies on the crucial step of sample preparation. Complex and expensive workflows are significant challenges. At Revvity, we are ...
The Global DNA Sequencing Market was valued at USD 14.8 Billion in 2024, and is expected to reach USD 34.8 Billion by 2029, rising at a CAGR of 18.60%. The report highlights the current and future ...
SAN FRANCISCO, Nov. 13, 2025 /PRNewswire/ -- The global next-generation sequencing market size is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. The next ...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results